BCEL - Atreca, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.34
-0.08 (-0.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 10.42
Open 10.62
Bid 10.34 x 800
Ask 11.25 x 800
Day's Range 10.10 - 10.62
52 Week Range 10.01 - 23.65
Volume 65,909
Avg. Volume 106,951
Market Cap 288.98M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -18.88
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.20
Trade prices are not sourced from all markets
  • Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)?
    Simply Wall St.

    Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)?

    Every investor in Atreca, Inc. (NASDAQ:BCEL) should be aware of the most powerful shareholder groups. Institutions...

  • GlobeNewswire

    Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors

    Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to the company’s Board of Directors. In addition, Lawrence Steinman, M.D., Stanford University Professor and co-founder of Atreca, has resigned from the Board, effective as of August 22, 2019, but will continue to serve as a technical advisor to the company. “As we prepare to submit an Investigational New Drug (IND) application for ATRC-101 later this year and enter the clinic in early 2020, Lindsey’s deep oncology expertise and her experience in the development of oncology therapeutics will be critical as the company continues to evolve,” said John Orwin, Chief Executive Officer.

  • Barrons.com

    Stanford University Now Owns Stakes in Uber and Pinterest Stock

    Stanford University owns shares of Uber, CrowdStrike, and Pinterest. It also acquired a stake in biotech stock Atreca in the second quarter and slashed its investment in Dropbox.

  • GlobeNewswire

    Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

    REDWOOD CITY, Calif., Aug. 13, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

  • Benzinga

    Stifel: Atreca Offers Attractive Oncology Drug Development Play

    Atreca has a highly differentiated approach to antibody drug discovery that moves completely away from the biologically or genetically derived hypotheses that are traditionally used to inform target selection, Willey said in a Monday initiation note.

  • GlobeNewswire

    Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

    Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel. As Chief Business Officer, Dr. Decker will lead Atreca’s corporate development function, including its strategic partnering initiatives and alliance management.

  • Benzinga

    Atreca Opens For Trade

    Atreca, Inc. (NASDAQ: BCEL ) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17. Atreca is a biopharma company that uses its platform to discover and develop ...

  • GlobeNewswire

    Atreca Announces Pricing of Initial Public Offering

    REDWOOD CITY, Calif., June 19, 2019 -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel.

  • Benzinga

    Atreca IPO: What You Need To Know

    Cancer biotechs are the hottest among drug development companies, given the lucrative market opportunity before them. One such company is testing the IPO waters this week. The IPO Terms Redwood, California-based ...

  • Benzinga

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...